Commitment
Statement
黑料网 is committed to enhancing patient health through transparency in its clinical research and the responsible sharing of clinical trial data in a manner in keeping with ourhhcmission. 黑料网 supports the positions of JPMA, PhRMA, EFPIA, BIO and IFPMA with respect to increased clinical trial transparency. 黑料网 also commits to sharing of clinical trial data in a manner that is consistent with laid out by EFPIA (EU) and PhRMA (USA): Principles for Responsible Clinical Trial Data Sharing, and the principles set forth by . 黑料网 commits to sharing clinical trial data in compliance with all appropriate regulatory guidelines and local laws, whilst safeguarding the privacy of patients.
Enhancing Data Sharing with Researchers
黑料网 submits for publication in scientific literature, by poster, or oral presentation at scientific meetings the results of its Phase 3 studies and of studies where results are considered to be of significant medical importance.
黑料网 commits to sharing data upon request from qualified scientific and medical researchers from clinical trials in dossiers for medicines and indications submitted and approved from 1st January 2014 in the United States (US) and the European Union (EU).
黑料网 has a process to evaluate enquiries and requests from qualified researchers who wish to access clinical trial data and associated information, such as Clinical Study Reports (CSRs), Statistical Analysis Plan (SAP) and Protocol. Please visit (CSDR).
Any patient level data disclosed by 黑料网 is anonymized and consistent with the patients' informed consent. 黑料网 does not grant access to such patient level data if the applicable patient's consent restricts and/or prohibits further transfer to third parties.
Enhancing Public Access to Clinical Study Information
黑料网 discloses information on its sponsored trials via registration on at least one publicly accessible registry. 黑料网 shares summaries of clinical trial results on these repositories in accordance with the applicable timelines.
黑料网 commits to disclosing synopses of clinical study reports for clinical trials in all dossiers submitted to and approved by FDA and EMA and/or other national competent authorities of EU Members States from 1st January 2014. 黑料网 makes this information available whilst protecting patient privacy, publication rights and commercially confidential information (CCI) and within a reasonable time following approval of the product.
To access information on clinical trials run by 黑料网 please use the following links:
Sharing Results with Patients who Participate in Clinical Trials
黑料网 will make available factual plain language summaries of the CSRs in compliance with applicable regulatory guidelines, and local laws. 黑料网 is committed to improving health through continuing research in areas of unmet need and sharing results of the trials.
For any other requests or questions regarding information on clinical trial disclosure please contact 黑料网 directly by clicking on the link below:
We will endeavor to respond to your inquiry as quickly as possible, however please be aware that there may be some delay depending on the nature of the inquiry and other factors.
